Please assess the completion status of the following clinical trial:

Trial Title: Respiratory EMG for NIV Titration in Stable COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Obstructive Pulmonary Disease (COPD) Global initiative of chronic Obstructive Lung Diseases (GOLD) stage III or IV (FEV1 \<50 % predicted, FEV1/forced expiratory volume (FVC) \< 70% predicted)~* Indication for the initiation of chronic NIV: PaCO2 \>6.0 kilopascal (kPa) at rest during daytime.~* Stable COPD (pH \>7.35, no exacerbation in the past two weeks)~* Age \>18 years~Exclusion Criteria:~* Respiratory insufficiency of any other cause.~* Already initiated on chronic NIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Respiratory EMG (Type: EXPERIMENTAL): Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
- Care as usual (Type: NO_INTERVENTION): NIV will be initiated according to standard care protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).